CXCR4 and hepatocellular carcinoma: To validate the role of CXCL12 in modulating B cell functions in vivo, we applied a mouse liver orthotopic xenograft model using stably overexpressing PRP19 HCC cells and treated them with the CXCL12 and CXCR4 inhibitor plerixafor (Figure 4H).